The estimated Net Worth of Michael P. Tarnok is at least $462 Tausend dollars as of 21 May 2024. Mr. Tarnok owns over 30,000 units of Dyadic International stock worth over $307,629 and over the last 5 years he sold DYAI stock worth over $0. In addition, he makes $154,000 as Independent Chairman of the Board at Dyadic International.
Sign up
Mr. Tarnok DYAI stock SEC Form 4 insiders trading
Michael has made over 2 trades of the Dyadic International stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 30,000 units of DYAI stock worth $40,800 on 21 May 2024.
The largest trade he's ever made was exercising 30,000 units of Dyadic International stock on 21 May 2024 worth over $40,800. On average, Michael trades about 6,353 units every 16 days since 2019. As of 21 May 2024 he still owns at least 246,103 units of Dyadic International stock.
You can see the complete history of Mr. Tarnok stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Tarnok biography
Michael P. Tarnok serves as Independent Chairman of the Board of the Company. Michael P. Tarnok joined the Board on June 12, 2014 and has served on the Company’s Audit, Nominating and Compensation Committees, and on January 12, 2015 Mr. Tarnok was appointed Dyadic’s Chairman of the Board. Mr. Tarnok is also currently a board member of Ionetix, Inc. In addition, Mr. Tarnok’s prior board service includes Global Health Council, and Keryx Biopharmaceuticals, Inc., where he also served as Chairman of the board of directors. Mr. Tarnok is a seasoned finance and operational executive with extensive pharmaceutical industry experience in a wide range of functional areas. He spent the majority of his career at Pfizer Inc., which he joined in 1989 as Finance Director-US Manufacturing and from 2000 to 2007 served as a Senior Vice President in Pfizer’s US Pharmaceutical Division. In this position, Mr. Tarnok managed multiple responsibilities for the division including, finance, access contracting, trade management, information technology, Sarbanes-Oxley compliance and the Greenstone generics division. Prior to joining Pfizer, Mr. Tarnok worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation and Olivetti Corporation of America. Mr. Tarnok earned an M.B.A. in Marketing from New York University and a B.S. in Accounting from St. John’s University.
What is the salary of Michael Tarnok?
As the Independent Chairman of the Board of Dyadic International, the total compensation of Michael Tarnok at Dyadic International is $154,000. There are 9 executives at Dyadic International getting paid more, with Mark Emalfarb having the highest compensation of $1,074,050.
How old is Michael Tarnok?
Michael Tarnok is 65, he's been the Independent Chairman of the Board of Dyadic International since 2015. There are 3 older and 7 younger executives at Dyadic International. The oldest executive at Dyadic International, Inc. is Jack Kaye, 76, who is the Independent Director.
What's Michael Tarnok's mailing address?
Michael's mailing address filed with the SEC is C/O DYADIC INTERNATIONAL, INC., 1044 NORTH U.S. HIGHWAY ONE, SUITE 201, JUPITER, FL, 33477-5094.
Insiders trading at Dyadic International
Over the last 6 years, insiders at Dyadic International have traded over $118,246,658,250 worth of Dyadic International stock and bought 27,000 units worth $100,230 . The most active insiders traders include Mark A Emalfarb, Ronen Tchelet und Seth Herbst. On average, Dyadic International executives and independent directors trade stock every 73 days with the average trade being worth of $54,365. The most recent stock trade was executed by Barry Buckland on 11 June 2024, trading 11,793 units of DYAI stock currently worth $18,751.
What does Dyadic International do?
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.
What does Dyadic International's logo look like?
Complete history of Mr. Tarnok stock trades at Dyadic International
Dyadic International executives and stock owners
Dyadic International executives and other stock owners filed with the SEC include:
-
Mark Emalfarb,
President, Chief Executive Officer, Director -
Mark A. Emalfarb,
Founder, CEO, Pres & Director -
Matthew Jones,
Managing Director - Business Development and Licensing -
Ping Rawson,
Chief Financial Officer, Chief Accounting Officer -
Matthew S. Jones,
Managing Director of Bus. Devel. & Licensing -
Ronen Tchelet,
Vice President of Research and Business Development -
Dr. Ronen Tchelet Ph.D.,
VP of Research & Bus. Devel. -
Jack Kaye,
Independent Director -
Arindam Bose,
Independent Director -
Michael Tarnok,
Independent Chairman of the Board -
Seth Herbst,
Independent Director -
Barry Buckland,
Independent Director -
Ana Gómez Rodriguez,
Sec. of the Board -
Joseph P. Hazelton,
Chief Bus. Officer -
Patrick K. Lucy,
Director -
Trust Under Agreement Dated...,
10% owner -
Joseph P Hazelton,
Chief Business Officer